Your browser doesn't support javascript.
loading
A common antigenic motif recognized by naturally occurring human VH5-51/VL4-1 anti-tau antibodies with distinct functionalities.
Apetri, Adrian; Crespo, Rosa; Juraszek, Jarek; Pascual, Gabriel; Janson, Roosmarijn; Zhu, Xueyong; Zhang, Heng; Keogh, Elissa; Holland, Trevin; Wadia, Jay; Verveen, Hanneke; Siregar, Berdien; Mrosek, Michael; Taggenbrock, Renske; Ameijde, Jeroenvan; Inganäs, Hanna; van Winsen, Margot; Koldijk, Martin H; Zuijdgeest, David; Borgers, Marianne; Dockx, Koen; Stoop, Esther J M; Yu, Wenli; Brinkman-van der Linden, Els C; Ummenthum, Kimberley; van Kolen, Kristof; Mercken, Marc; Steinbacher, Stefan; de Marco, Donata; Hoozemans, Jeroen J; Wilson, Ian A; Koudstaal, Wouter; Goudsmit, Jaap.
Afiliação
  • Apetri A; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands. AApetri@its.jnj.com.
  • Crespo R; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
  • Juraszek J; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
  • Pascual G; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, 3210 Merryfield Row, San Diego, CA, 92121, USA.
  • Janson R; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
  • Zhu X; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
  • Zhang H; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
  • Keogh E; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, 3210 Merryfield Row, San Diego, CA, 92121, USA.
  • Holland T; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, 3210 Merryfield Row, San Diego, CA, 92121, USA.
  • Wadia J; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, 3210 Merryfield Row, San Diego, CA, 92121, USA.
  • Verveen H; Present address: Janssen R&D US, 3210 Merryfield Row, San Diego, CA, 92121, USA.
  • Siregar B; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
  • Mrosek M; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
  • Taggenbrock R; Proteros Biostructures GmbH, Bunsenstraße 7a, 82152, Planegg, Germany.
  • Ameijde J; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
  • Inganäs H; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
  • van Winsen M; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
  • Koldijk MH; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
  • Zuijdgeest D; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
  • Borgers M; Janssen Vaccines and Prevention, Janssen Pharmaceutical Companies of Johnson and Johnson, Archimedesweg 6, Leiden, CN, 2333, the Netherlands.
  • Dockx K; Janssen Neuroscience Discovery, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340, Beerse, Belgium.
  • Stoop EJM; Molecular and Cellular Pharmacology, Discovery Sciences, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340, Beerse, Belgium.
  • Yu W; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
  • Brinkman-van der Linden EC; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
  • Ummenthum K; Janssen Prevention Center, Janssen Pharmaceutical Companies of Johnson & Johnson, Archimedesweg 6, 2333, CN, Leiden, the Netherlands.
  • van Kolen K; Department of Pathology, Amsterdam Neuroscience, VU University Medical Center, De Boelelaan 1117, 1081, HV, Amsterdam, the Netherlands.
  • Mercken M; Janssen Neuroscience Discovery, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340, Beerse, Belgium.
  • Steinbacher S; Janssen Neuroscience Discovery, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340, Beerse, Belgium.
  • de Marco D; Proteros Biostructures GmbH, Bunsenstraße 7a, 82152, Planegg, Germany.
  • Hoozemans JJ; Janssen Neuroscience Discovery, Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340, Beerse, Belgium.
  • Wilson IA; Department of Pathology, Amsterdam Neuroscience, VU University Medical Center, De Boelelaan 1117, 1081, HV, Amsterdam, the Netherlands.
  • Koudstaal W; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
  • Goudsmit J; Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, 92037, USA.
Acta Neuropathol Commun ; 6(1): 43, 2018 05 31.
Article em En | MEDLINE | ID: mdl-29855358
ABSTRACT
Misfolding and aggregation of tau protein are closely associated with the onset and progression of Alzheimer's Disease (AD). By interrogating IgG+ memory B cells from asymptomatic donors with tau peptides, we have identified two somatically mutated VH5-51/VL4-1 antibodies. One of these, CBTAU-27.1, binds to the aggregation motif in the R3 repeat domain and blocks the aggregation of tau into paired helical filaments (PHFs) by sequestering monomeric tau. The other, CBTAU-28.1, binds to the N-terminal insert region and inhibits the spreading of tau seeds and mediates the uptake of tau aggregates into microglia by binding PHFs. Crystal structures revealed that the combination of VH5-51 and VL4-1 recognizes a common Pro-Xn-Lys motif driven by germline-encoded hotspot interactions while the specificity and thereby functionality of the antibodies are defined by the CDR3 regions. Affinity improvement led to improvement in functionality, identifying their epitopes as new targets for therapy and prevention of AD.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoglobulina G / Linfócitos B / Proteínas tau / Cadeias Pesadas de Imunoglobulinas / Cadeias Leves de Imunoglobulina Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Acta Neuropathol Commun Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Imunoglobulina G / Linfócitos B / Proteínas tau / Cadeias Pesadas de Imunoglobulinas / Cadeias Leves de Imunoglobulina Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Acta Neuropathol Commun Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Holanda